Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China · Delayed Price · Currency is CNY 27.93
-0.15 (-0.53%)
Sep 18, 2025, 9:45 AM CST
SHA:688319 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 61.9 | 20.76 | 17.56 | 26.58 | 107.96 | 36.13 | Upgrade |
Depreciation & Amortization | 33.47 | 31.65 | 30.81 | 25.3 | 23.04 | 17.62 | Upgrade |
Other Amortization | 5.22 | 4.35 | 3.15 | 3.43 | 1.64 | 0.32 | Upgrade |
Loss (Gain) From Sale of Assets | 0.02 | 0.03 | 0.15 | 0.15 | 0.01 | - | Upgrade |
Asset Writedown & Restructuring Costs | 0.01 | - | - | - | - | -0 | Upgrade |
Loss (Gain) From Sale of Investments | -0.83 | -0.86 | -1.04 | -3.7 | -3.76 | -0.22 | Upgrade |
Provision & Write-off of Bad Debts | 20.36 | 10.19 | 1.72 | 12.18 | 9 | 5.49 | Upgrade |
Other Operating Activities | 15.23 | 6.67 | 5.66 | 9.13 | 0.12 | 3.06 | Upgrade |
Change in Accounts Receivable | -155.34 | -83.63 | 0.98 | -151.92 | -147.16 | -78.61 | Upgrade |
Change in Inventory | 3.93 | -13.57 | 1.68 | -7.96 | -27.28 | -14.34 | Upgrade |
Change in Accounts Payable | 48.77 | 19.06 | -12.3 | 64.46 | 81.2 | 51.65 | Upgrade |
Operating Cash Flow | 28.36 | -9.73 | 44 | -24.55 | 39.96 | 21.09 | Upgrade |
Operating Cash Flow Growth | 297.14% | - | - | - | 89.49% | - | Upgrade |
Capital Expenditures | -137.9 | -207.32 | -169.88 | -200.69 | -69.71 | -38.85 | Upgrade |
Sale of Property, Plant & Equipment | 0.06 | 0.03 | - | - | 0.01 | 0 | Upgrade |
Investment in Securities | 42.4 | -17.5 | 90 | 140 | -190 | -10 | Upgrade |
Other Investing Activities | 0.83 | 0.86 | 1.04 | 3.7 | 3.76 | 0.22 | Upgrade |
Investing Cash Flow | -94.61 | -223.93 | -78.84 | -56.99 | -255.94 | -48.63 | Upgrade |
Short-Term Debt Issued | - | - | - | - | - | 25 | Upgrade |
Long-Term Debt Issued | - | 206.82 | 208.25 | 129.99 | 35 | 1.5 | Upgrade |
Total Debt Issued | 149.46 | 206.82 | 208.25 | 129.99 | 35 | 26.5 | Upgrade |
Short-Term Debt Repaid | - | - | - | - | - | -5 | Upgrade |
Long-Term Debt Repaid | - | -78.85 | -100.06 | -40 | -27.34 | -2.37 | Upgrade |
Total Debt Repaid | -116.88 | -78.85 | -100.06 | -40 | -27.34 | -7.37 | Upgrade |
Net Debt Issued (Repaid) | 32.58 | 127.97 | 108.19 | 89.99 | 7.66 | 19.13 | Upgrade |
Issuance of Common Stock | - | - | 10.38 | 17.65 | 371.81 | - | Upgrade |
Repurchase of Common Stock | -2.39 | -2.39 | - | - | - | - | Upgrade |
Common Dividends Paid | -14.25 | -29.68 | -5.99 | -4.25 | -1.03 | - | Upgrade |
Other Financing Activities | -0.96 | - | 16.68 | - | -9.64 | -0.75 | Upgrade |
Financing Cash Flow | 14.98 | 95.91 | 129.27 | 103.38 | 368.79 | 18.37 | Upgrade |
Net Cash Flow | -51.27 | -137.76 | 94.42 | 21.84 | 152.82 | -9.17 | Upgrade |
Free Cash Flow | -109.53 | -217.05 | -125.88 | -225.24 | -29.75 | -17.76 | Upgrade |
Free Cash Flow Margin | -16.39% | -36.86% | -25.37% | -41.14% | -6.11% | -5.55% | Upgrade |
Free Cash Flow Per Share | -0.27 | -0.54 | -0.31 | -0.56 | -0.08 | -0.05 | Upgrade |
Cash Interest Paid | 0.96 | - | - | - | - | 0.57 | Upgrade |
Cash Income Tax Paid | 35.39 | 25.59 | 34.19 | 35 | 16.56 | 11.92 | Upgrade |
Levered Free Cash Flow | -92.83 | -198.15 | -140.57 | -198.44 | -67.11 | -16.66 | Upgrade |
Unlevered Free Cash Flow | -83.15 | -189.11 | -136.09 | -195.27 | -66.34 | -16.31 | Upgrade |
Change in Working Capital | -107.03 | -82.52 | -14 | -97.61 | -98.05 | -41.31 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.